Synlogic
Medicines to perform metabolic functions to treat diseases throughout the body.
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 3 % | (12 %) | (75 %) | 222 % | (33 %) | 186 % | (100 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1824 %) | (2446 %) | (11095 %) | (3464 %) | (5392 %) | (1520 %) | (175088 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1922 %) | (2310 %) | (10857 %) | (3453 %) | (5606 %) | (1699 %) | (291988 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1509 % | 1884 % | 8711 % | 2687 % | 4411 % | 1304 % | 114425 % |
Source: Company filings or news article
Related Content
Synlogic, Inc. operates in the biotechnology sector, focusing on the development of synthetic biology-based therapeutics. The company engineers bacteria to perform specific functions within the human body, targeting complex diseases that are difficult to treat with traditional methods. Synlogic's primary clients include healthcare providers and pharmaceutical companies. The company operates in the global healthcare market, leveraging its proprietary technology to create novel treatments. Synlogic generates revenue through research and development partnerships, grants, and potential future product sales. Key products in development include SYNB1891, aimed at stimulating immune responses in challenging tumors.
Keywords: synthetic biology, bacterial therapeutics, complex diseases, immune response, healthcare, biotechnology, engineered bacteria, R&D partnerships, SYNB1891, pharmaceutical.